CDK9 and cancer: Based on these results, specific CDK9 inhibitors and identification of a new Bay 61–3606 target for Mcl-1 degradation may be beneficial for the treatment of cancers in which Mcl-1 contributes to the development of resistance to anticancer therapeutics.